Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2021 16:30 ET | Source: Advaxis, Inc.

Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...
April 26, 2021 11:07 ET | Source: Advaxis, Inc.

UPDATE - Advaxis Announces Achievement of Second Milestone Under ADXS-HER2 Licensing Agreement with OS Therapies

PRINCETON, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...
April 26, 2021 08:00 ET | Source: Advaxis, Inc.

Advaxis Announces Receipt of Second Milestone Payment Under ADXS-HER2 Licensing Agreement with OS Therapies

PRINCETON, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...
April 12, 2021 08:30 ET | Source: Advaxis, Inc.

Advaxis, Inc. Announces $20 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PRINCETON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of...
April 10, 2021 08:31 ET | Source: Advaxis, Inc.

Advaxis Presents Translational Biomarker Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the American Associated for Cancer Research (AACR) 2021 Annual Meeting

Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells during PD-1 blockade Assay enables determination of PD-1...
April 05, 2021 08:00 ET | Source: Advaxis, Inc.

Advaxis Announces Agreement with Columbia University Irving Medical Center to Fund Phase 1 Study of ADXS-504 for the Treatment of Early Prostate Cancer

PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...
March 23, 2021 11:33 ET | Source: Advaxis, Inc.

Advaxis to Present Corporate Overview at the Benzinga Biotech Small Cap Conference

PRINCETON, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...
March 16, 2021 09:00 ET | Source: Advaxis, Inc.

Advaxis Reports First Quarter Ended January 31, 2021 Financial Results and Provides a Business Update

Continued enrollment in expanded ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors ADXS-503 Phase 1/2 trial data presented at SITC...
March 12, 2021 08:00 ET | Source: Advaxis, Inc.

Advaxis to Present at the American Association for Cancer Research (AACR) 2021 Annual Meeting

PRINCETON, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...
January 25, 2021 07:00 ET | Source: Advaxis, Inc.

Advaxis Reports Fiscal Year 2020 Financial Results and Provides a Business Update

Enrolling strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and/or restore sensitivity to checkpoint inhibitors SITC presentation from ongoing ADXS-503 Phase 1/2...